Promising Results from Phase 2 Trial of Barzolvolimab in Chronic Spontaneous Urticaria Patients
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has recently shared exciting news regarding the 12-week results from their Phase 2 clinical trial of ...
Tag: CLDX
Teachers Retirement System of Kentucky Sells 22.4% Stake in Biopharmaceutical Company Celldex Therapeutics
Teachers Retirement System of The State of Kentucky, a prominent institutional investor, recently reduced its stake in biopharmaceutical company Celldex ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
